Hims & Hers Health (NYSE:HIMS) Stock Price Up 1.4% - Should You Buy?

Key Points

• Hims & Hers Health's stock price increased by 1.4% to $43.97, with a significant drop in trading volume to approximately 9.55 million shares, a decrease of 72% from average levels.
• Recent analyst updates include Bank of America raising its price target from $22 to $26, while Truist Financial lowered its target from $48 to $37, and overall, the stock has a consensus rating of "Reduce" with an average price target of $38.92.
• The company reported earnings of $0.17 per share, slightly missing analyst expectations, but showing a 72.6% year-over-year increase in revenue to $544.83 million.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) shares rose 1.4% during trading on Thursday . The stock traded as high as $44.63 and last traded at $43.97. Approximately 9,551,143 shares traded hands during mid-day trading, a decline of 72% from the average daily volume of 33,640,988 shares. The stock had previously closed at $43.38.

Analyst Ratings Changes

HIMS has been the subject of several recent research reports. Bank of America boosted their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research report on Tuesday, April 29th. Piper Sandler reissued a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Truist Financial dropped their target price on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research note on Monday. Finally, Zacks Research downgraded Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday. Two analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Trading Up 1.7%

The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The company has a 50 day simple moving average of $52.18 and a two-hundred day simple moving average of $45.73. The firm has a market cap of $9.97 billion, a PE ratio of 55.03, a P/E/G ratio of 2.85 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,572 shares of the business's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $51.64, for a total transaction of $132,818.08. Following the sale, the insider owned 153,021 shares in the company, valued at approximately $7,902,004.44. The trade was a 1.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patrick Harrison Carroll sold 60,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the sale, the insider owned 169,940 shares in the company, valued at approximately $9,105,385.20. The trade was a 26.09% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,396,090 shares of company stock worth $71,927,627 in the last 90 days. 13.71% of the stock is owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently modified their holdings of HIMS. Envestnet Asset Management Inc. boosted its stake in shares of Hims & Hers Health by 139.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 78,686 shares of the company's stock worth $1,903,000 after buying an additional 45,791 shares during the last quarter. Mariner LLC boosted its stake in shares of Hims & Hers Health by 77.4% in the fourth quarter. Mariner LLC now owns 19,943 shares of the company's stock worth $482,000 after buying an additional 8,699 shares during the last quarter. Guggenheim Capital LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth about $274,000. NewEdge Advisors LLC boosted its stake in shares of Hims & Hers Health by 83.4% in the fourth quarter. NewEdge Advisors LLC now owns 20,021 shares of the company's stock worth $484,000 after buying an additional 9,105 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of Hims & Hers Health by 46.5% in the fourth quarter. First Trust Advisors LP now owns 355,103 shares of the company's stock worth $8,586,000 after buying an additional 112,772 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.